Metoprolol, 1 mg/ml 5 pcs 5 pcs

Pharmacotherapeutic group:

β1-adrenoblocker selective

ATX:

C.07.A.B Selective beta1-adrenoblockers

C.07.A.B.02 Metoprolol

Pharmacodynamics:

In patients with myocardial infarction, intravenous metoprolol reduces chest pain and reduces the risk of atrial fibrillation and flutter. Intravenous metoprolol administration at the first symptoms (within 24 hours of the appearance of the first symptoms) reduces the risk of myocardial infarction.

Early initiation of metoprolol treatment leads to an improved further prognosis of myocardial infarction treatment.

A reduction in heart rate (HR) in paroxysmal tachycardia and atrial fibrillation (flutter) is achieved.

Metoprolol is a β1-adrenoblocker that blocks β1-receptors at doses significantly lower than those required to block p2-receptors. Metoprolol has little membrane-stabilizing effect and no partial agonist activity. Metoprolol reduces or inhibits the agonist effect that catecholamines produced by nervous and physical stress have on cardiac activity.

This means that metoprolol has the ability to inhibit the increase in heart rate, minute volume and myocardial contractility, as well as the rise in blood pressure (BP) caused by the sudden release of catecholamines.

Patients with symptoms of obstructive lung disease may be prescribed metoprolol in combination with β2-adrenomimetics if necessary. When co-administration with β2-adrenomimetics, metoprolol, in therapeutic doses, has less effect on bronchodilation induced by β2-adrenomimetics than non-selective β-adrenoblockers.

Metoprolol has less effect than non-selective β-adrenoblockers on insulin production and carbohydrate metabolism. The effect of Metoprolol on the response of the cardiovascular system (CVS) in hypoglycemia is significantly less pronounced compared to non-selective β-adrenoblockers. Improved quality of life during treatment with Metoprolol was observed in patients after myocardial infarction.

Pharmacokinetics:

Metoprolol undergoes oxidative metabolism in the liver with the formation of three main metabolites, none of which has clinically significant β-blocking effect. About 5% of the administered dose is excreted unchanged in the urine. The average blood plasma elimination half-life of metoprolol is about 3-5 hours.

Indications

Interventricular tachycardia;

Prevention and treatment of myocardial ischemia, tachycardia, and pain in myocardial infarction or suspected myocardial infarction.

Active ingredient

Composition

1 ml of the solution contains:

The active ingredient:

Metoprolol tartrate – 1.0 mg.

Auxiliary substances:

Sodium chloride – 9.0 mg,

Water for injection – up to 1 ml.

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use

Similarities